Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21719732 | 0.80 | KDM4E (0.50) | KDM4ELMNA | |
| SCHEMBL16487838 | 0.77 | PTGS1 (0.51) | RAB9ANPC1HDAC3HDAC4HDAC1 | |
| SCHEMBL2611106 | 0.76 | PKM (0.45) | RAB9ANPC1HDAC3HDAC4HDAC1 | |
| SCHEMBL3279759 | 0.76 | KDM4E (0.42) | RAB9ANPC1HDAC3HDAC4HDAC1 | |
| SCHEMBL365942 | 0.76 | RAB9A (0.40) | RAB9ANPC1HDAC3HDAC4HDAC1 | |
| SCHEMBL938217 | 0.76 | RAB9A (0.40) | RAB9ANPC1HDAC3HDAC4HDAC1 | |
| SCHEMBL21720880 | 0.75 | KDM4E (0.35) | ALDH1A1KDM4EPTGS2PTGS1LMNA | |
| SCHEMBL946905 | 0.74 | KMT2A (0.45) | RAB9ANPC1HDAC3HDAC4HDAC1 | |
| SCHEMBL16347374 | 0.74 | PTGS1 (0.39) | RAB9ANPC1HDAC3HDAC4HDAC1 | |
| SCHEMBL1463361 | 0.74 | HDAC3 (0.41) | RAB9ANPC1HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MYOKARDIA INC (US) | 2025-09-04 | — | — | US | disclosed |
| EP-3143026-B1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS AG (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-4234017-A2 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) | MyoKardia, Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3247707-B1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) | MYOKARDIA INC (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3247707-B1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS USEFUL FOR THE TREATMENT OF CARDIAC DISORDERS SUCH AS DILATED CARDIOMYOPATHY (DCM) | MYOKARDIA INC (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MyoKardia, Inc. | 2022-04-21 | — | — | US | disclosed |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | MyoKardia, Inc. | 2022-04-21 | — | — | US | disclosed |
| US-11123337-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | MyoKardia, Inc. (US) | 2021-09-21 | — | — | US | disclosed |
| US-11123337-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | MyoKardia, Inc. (US) | 2021-09-21 | — | — | US | disclosed |
| WO-2021057975-A1 | MUTANT IDH2 INHIBITOR AND APPLICATION THEREOF | 贝达药业股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| US-9925177-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | MyoKardia, Inc. (US) | 2018-03-27 | — | — | US | disclosed |
| US-9925177-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | MyoKardia, Inc. (US) | 2018-03-27 | — | — | US | disclosed |
| EP-3247707-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY (DCM) | Myokardia, Inc. (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170239227-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-08-24 | — | — | US | disclosed |
| US-9688689-B2 | Compounds and compositions for inducing chondrogenesis | NOVARTIS AG (CH) | 2017-06-27 | — | — | US | disclosed |
| US-20160243100-A1 | 4-Methylsulfonyl-Substituted Piperidine Urea Compounds | MyoKardia, Inc. | 2016-08-25 | — | — | US | disclosed |
| US-20160243100-A1 | 4-Methylsulfonyl-Substituted Piperidine Urea Compounds | MyoKardia, Inc. | 2016-08-25 | — | — | US | disclosed |
| WO-2016118774-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY (DCM) | MyoKardia, Inc. (US) | 2016-07-28 | — | — | WO | disclosed |
| WO-2016118774-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS FOR THE TREATMENT OF DILATED CARDIOMYOPATHY (DCM) | MyoKardia, Inc. (US) | 2016-07-28 | — | — | WO | disclosed |
| EP-2549875-B1 | SOLUBLE GUANYLATE CYCLASE ACTIVATORS | MERCK SHARP & DOHME (US) | 2015-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275952-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | RAB9A 1864/4885NPC1 2311/4885HDAC3 996/4885 |
| US-20220117955-A1 | 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS | TNNI3, UMPS, TNNT2 | RAB9A 1864/4885NPC1 2311/4885HDAC3 996/4885 |
| US-20170239227-A1 | COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS | FGF1, COL2A1, FGFR3 | RAB9A 2432/4885NPC1 3459/4885HDAC3 484/4885 |
| US-20160243100-A1 | 4-Methylsulfonyl-Substituted Piperidine Urea Compounds | TNNI3, UMPS, TNNT2 | RAB9A 1864/4885NPC1 2311/4885HDAC3 996/4885 |
| US-11123337-B2 | 4-methylsulfonyl-substituted piperidine urea compounds | TNNI3, UMPS, TNNT2 | RAB9A 1864/4885NPC1 2311/4885HDAC3 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.